Metformin as a host-directed therapeutic in tuberculosis: Is there a promise?

Wing Wai Yew, Kwok Chiu Chang, Denise P. Chan, Ying Zhang

Research output: Contribution to journalReview article

Abstract

To complement the development of new or repurposed drugs for improving the treatment outcomes of drug-susceptible and drug-resistant tuberculosis, current insight also focuses on the use of host-directed therapy. Metformin, a drug often used in the management of type 2 diabetes mellitus, has attracted attention by virtue of its favourable activity as an adjunctive agent against tuberculosis, discovered through laboratory and clinical studies. To definitively establish its role as a host-directed therapeutic in tuberculosis, more preclinical and clinical research is still required to better delineate its mechanism(s) of action and optimal clinical use.

Original languageEnglish (US)
Pages (from-to)76-80
Number of pages5
JournalTuberculosis
Volume115
DOIs
StatePublished - Mar 2019

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Metformin as a host-directed therapeutic in tuberculosis: Is there a promise?'. Together they form a unique fingerprint.

  • Cite this